Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Drugs topic
No spam. Unsubscribe anytime.
Senate amends and approves insulin access bill, shortening emergency supply window to 60 days
Summary
After extensive floor debate about access in rural areas, the Senate adopted an amendment to reduce an emergency insulin supply provision from 90 to 60 days and passed House Bill 207 to expand emergency dispensing, price options and insurer pathways to lower insulin costs.
The Utah Senate on March 10 passed Second Substitute House Bill 207, a bipartisan bill aimed at easing insulin access and lowering out‑of‑pocket costs for Utahns who rely on the life‑saving medicine.
Sponsor Senator Henderson described HB207 as a comprehensive approach: it allows pharmacists to dispense an emergency supply of insulin when a patient has no refills or an expired prescription, permits any Utahn to purchase insulin at the 75% discount available to public‑employee health plan members, and gives insurers four paths to lower patient costs (a $30 monthly cap per prescription, placing insulin on the lowest cost tier, guaranteeing PEHP‑discount pricing with a $100 cap, or seeking a waiver from the insurance commissioner for an equivalent savings approach).
The bill drew focused floor debate about rural access and the appropriate size of an emergency dispensation. Senator Wyler described a parent’s concern that in rural Utah it can "usually take 90 days to get an appointment" with pediatric diabetes specialists; sponsors negotiated a compromise amendment by Senator Vickers to reduce the emergency supply window from 90 to 60 days. Senator Henderson framed the bill’s intent: "No Utahn should ever have to leave the pharmacy without the insulin that they need to live." The Senate approved the amended bill by roll call (28 yea, 0 nay, 1 absent).
Why it matters: Sponsors said the bill will address both immediate access problems — allowing pharmacists to provide an emergency supply — and cost barriers through insurer‑level options, with the stated goal of preventing insulin rationing and the severe health consequences that follow.
Next steps: The bill will be enrolled, signed by the President, and returned to the House for the Speaker’s signature.
